Syntara Raises $8.84M to Fund Five Clinical Trial Readouts
Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.
- SPP raised $0.84 million at 15.6% discount
- Total capital raise reaches $8.84 million
- Funds to support five clinical trial readouts in 2026
- Preparation underway for Phase 2b myelofibrosis study
- Patent strengthening and licensing discussions prioritized
Capital Raise Completes at Discounted Price
Syntara Limited (ASX:SNT) has wrapped up its Share Purchase Plan (SPP), securing approximately A$0.84 million from eligible shareholders. The shares were offered at A$0.027 each, reflecting a 15.6% discount to the last closing price before the placement announcement and a 17.6% discount to the 5-day volume weighted average price. This latest raise supplements a prior $8 million placement, bringing the total capital raised to about $8.84 million before costs.
Funding Clinical Trials and Pipeline Progression
The freshly raised funds extend Syntara's cash runway through to the third quarter of 2027. The company plans to allocate capital towards five key clinical trial readouts scheduled for calendar year 2026, alongside advancing licensing discussions across its drug pipeline. Preparations for a pivotal Phase 2b study targeting myelofibrosis are also underway, with efforts focused on protocol finalisation, contract research organisation (CRO) selection, trial site negotiations, formulation development, and clinical trial supply logistics.
Expanding Patent Protection and Development Scope
Beyond clinical activities, Syntara is investing in strengthening its global pan-LOX patent portfolio. This strategic move aims to broaden the company's intellectual property coverage, enhancing its ability to exploit multiple therapeutic indications. The company also earmarks funds to cover costs associated with the capital raising offer.
Pipeline Highlights and Strategic Collaborations
Syntara's lead candidate, amsulostat (SNT-5505), targets myelofibrosis; a bone marrow cancer characterised by scar tissue buildup that impairs blood cell production. The drug holds Fast Track and FDA Orphan Drug designations and has completed Phase 2a trials both as monotherapy and combined with JAK inhibitors. Additional Phase 1c/2 studies are underway for myelodysplastic syndrome. Topical pan-LOX inhibitors like SNT-9465 and SNT-6302 are progressing in scar treatment trials, including collaborations with the University of Western Australia and Parkinson’s UK, targeting fibrosis and neuroinflammation respectively.
Shareholder Support and Market Positioning
The successful SPP reflects ongoing shareholder confidence in Syntara’s clinical and development strategy. By securing nearly $9 million in fresh capital, the company positions itself to navigate critical clinical milestones and patent developments that could shape its future licensing and commercial opportunities. The upcoming trial readouts and Phase 2b study preparations will be pivotal in determining Syntara’s trajectory in the competitive biotech landscape.
Bottom Line?
Syntara’s latest capital raise shores up funding for a busy 2026 clinical calendar, but the impact hinges on trial outcomes and licensing progress.
Questions in the middle?
- Will the five clinical trial readouts deliver data that materially advances Syntara’s valuation?
- How will the strengthened pan-LOX patent suite influence future licensing negotiations?
- What milestones in the Phase 2b myelofibrosis study will investors watch most closely?
